Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT03173248
Registration number
NCT03173248
Ethics application status
Date submitted
30/05/2017
Date registered
1/06/2017
Date last updated
5/04/2024
Titles & IDs
Public title
Study of AG-120 (Ivosidenib) vs. Placebo in Combination With Azacitidine in Participants With Previously Untreated Acute Myeloid Leukemia With an IDH1 Mutation
Query!
Scientific title
A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination With Azacitidine in Subjects = 18 Years of Age With Previously Untreated Acute Myeloid Leukemia With an IDH1 Mutation
Query!
Secondary ID [1]
0
0
AG120-C-009
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
AGILE
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Newly Diagnosed Acute Myeloid Leukemia (AML)
0
0
Query!
Untreated AML
0
0
Query!
AML Arising From Myelodysplastic Syndrome (MDS)
0
0
Query!
Leukemia, Myeloid, Acute
0
0
Query!
Condition category
Condition code
Cancer
0
0
0
0
Query!
Leukaemia - Acute leukaemia
Query!
Cancer
0
0
0
0
Query!
Leukaemia - Chronic leukaemia
Query!
Cancer
0
0
0
0
Query!
Children's - Leukaemia & Lymphoma
Query!
Blood
0
0
0
0
Query!
Haematological diseases
Query!
Blood
0
0
0
0
Query!
Other blood disorders
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - AG-120
Treatment: Drugs - Placebo
Treatment: Drugs - Azacitidine
Experimental: AG-120 + Azacitidine - Participants received AG-120 500 mg orally, once daily (QD) in combination with azacitidine 75 milligrams per square meter per day (mg/m^2/day) subcutaneously (SC) or intravenously (IV), on Days 1-7, or on Days 1-5 and 8-9, of each 28-day cycle for a minimum of 6 cycles until death, disease relapse, disease progression, development of unacceptable toxicity (adverse event), confirmed pregnancy, withdrawal by participant or protocol violation.
Placebo Comparator: Placebo + Azacitidine - Participants received AG-120 matching placebo orally, QD in combination with azacitidine 75 mg/m^2/day SC or IV, on Days 1-7, or on Days 1-5 and 8-9, of each 28-day cycle for a minimum of 6 cycles until death, disease relapse, disease progression, development of unacceptable toxicity (adverse event), confirmed pregnancy, withdrawal by participant or protocol violation .
Treatment: Drugs: AG-120
Tablets administered orally
Treatment: Drugs: Placebo
Tablets administered orally
Treatment: Drugs: Azacitidine
Administered SC or IV
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Event-Free Survival (EFS)
Query!
Assessment method [1]
0
0
EFS was defined as the time from randomization until treatment failure, relapse from remission, or death from any cause, whichever occurs first. Treatment failure was defined as failure to achieve complete remission (CR) by Week 24. CR: Bone marrow blasts <5% and no Auer rods; absence of extramedullary disease; Absolute neutrophil count (ANC) =1.0 × 10^9 per litre (10^9/L) (1000 per microlitre [1000/µL]); platelet count =100 × 10^9/L (100,000/µL); independence of red blood cell transfusions. Participants who had an EFS event (relapse or death) after, 2 or more missing disease assessments were censored at the last adequate disease assessment documenting no relapse before the missing assessments. The reported data represents the Kaplan-Meier median value.
Query!
Timepoint [1]
0
0
Up to Week 24
Query!
Secondary outcome [1]
0
0
Complete Remission Rate (CR Rate)
Query!
Assessment method [1]
0
0
CR rate is defined as the proportion of participants who achieve a CR. A Cochran-Mantel-Haenszel (CMH) test will be used to compare CR rate between the 2 treatment arms.
Query!
Timepoint [1]
0
0
Up to approximately 52 months
Query!
Secondary outcome [2]
0
0
Overall Survival (OS)
Query!
Assessment method [2]
0
0
OS is defined as the time from date of randomization to the date of death due to any cause. Kaplan-Meier (KM) curves and KM estimates of OS will be presented for each treatment arm.
Query!
Timepoint [2]
0
0
Up to approximately 52 months
Query!
Secondary outcome [3]
0
0
CR + Complete Remission With Partial Hematologic (CRh) Rate
Query!
Assessment method [3]
0
0
CR + CRh rate is defined as the proportion of participants who achieve a CR or CRh. CRh is defined as a CR with partial recovery of peripheral blood counts (less than 5% bone marrow blasts, absolute neutrophil count (ANC) greater than 0.5 × 10^9/liter (L) 500/microliter (µL)], and platelets greater than 50 × 10^9/L [50,000/µL]). A CMH test will be used to compare the CR + CRh rate between the 2 treatment arms.
Query!
Timepoint [3]
0
0
Up to approximately 52 months
Query!
Secondary outcome [4]
0
0
Objective Response Rate (ORR)
Query!
Assessment method [4]
0
0
ORR is defined as the rate of CR, CR with incomplete hematologic recovery (CRi) (including CR with incomplete platelet recovery [CRp]), partial remission (PR), and morphologic leukemia-free state (MLFS). The best response is calculated using the following hierarchy: CR, followed by CRi (including CRp), followed by PR and MLFS. A summary of best response by treatment arm will be produced. A CMH test will be used to compare ORR between the 2 treatment arms.
Query!
Timepoint [4]
0
0
Up to approximately 52 months
Query!
Secondary outcome [5]
0
0
CR + CRi (Including CRp) Rate
Query!
Assessment method [5]
0
0
The CR + CRi (including CRp) rate is defined as the proportion of participants who achieve a CR or CRi (including CRp). A CMH test will be used to compare the CR + CRi (including CRp) rate between the 2 treatment arms.
Query!
Timepoint [5]
0
0
Up to approximately 52 months
Query!
Secondary outcome [6]
0
0
Duration of CR (DOCR)
Query!
Assessment method [6]
0
0
DOCR will be calculated as the date of the first occurrence of CR to the date of first documented disease relapse, or death. DOCR is only defined for participants who achieve a CR.
Query!
Timepoint [6]
0
0
Up to approximately 52 months
Query!
Secondary outcome [7]
0
0
Duration of CRh (DOCRh)
Query!
Assessment method [7]
0
0
DOCRh will be calculated as the date of the first occurrence of CR or CRh to the date of first documented disease relapse or death. DOCRh is only defined for participants who achieve a CR or CRh.
Query!
Timepoint [7]
0
0
Up to approximately 52 months
Query!
Secondary outcome [8]
0
0
Duration of Response (DOR)
Query!
Assessment method [8]
0
0
DOR will be calculated as the date of the first response to the date of first documented disease relapse, disease progression, or death. DOR is only defined for participants who achieve a CR, CRi (including CRp), PR, and/or MLFS.
Query!
Timepoint [8]
0
0
Up to approximately 52 months
Query!
Secondary outcome [9]
0
0
Duration of CRi (DOCRi)
Query!
Assessment method [9]
0
0
DOCRi will be calculated as the date of the first occurrence of CR or CRi (including CRp) to the date of the first documented relapse or death. DOCRi is only defined for participants who achieve a CR or CRi (including CRp).
Query!
Timepoint [9]
0
0
Up to approximately 52 months
Query!
Secondary outcome [10]
0
0
Time to CR (TTCR)
Query!
Assessment method [10]
0
0
TTCR will be assessed from the date of randomization to the date of first occurrence of CR. TTCR is only defined for participants who achieve a CR.
Query!
Timepoint [10]
0
0
Up to approximately 52 months
Query!
Secondary outcome [11]
0
0
Time to CRh (TTCRh)
Query!
Assessment method [11]
0
0
TTCRh will be assessed from the date of randomization to the date of first occurrence of CR or CRh. TTCRh is only defined for participants who achieve a CR or CRh.
Query!
Timepoint [11]
0
0
Up to approximately 52 months
Query!
Secondary outcome [12]
0
0
Time to Response (TTR)
Query!
Assessment method [12]
0
0
TTR will be assessed from the date of randomization to the date of the first response. TTR is only defined for participants who achieve a CR, CRi (including CRp), PR, and/or MLFS.
Query!
Timepoint [12]
0
0
Up to approximately 52 months
Query!
Secondary outcome [13]
0
0
Time to CRi (TTCRi)
Query!
Assessment method [13]
0
0
TTCRi will be assessed from the date of randomization to the date of first occurrence of CR or CRi (including CRp). TTCRi is only defined for participants who achieve a CR or CRi (including CRp).
Query!
Timepoint [13]
0
0
Up to approximately 52 months
Query!
Secondary outcome [14]
0
0
Percentage of Participants With Abnormalities in Vital Sign Measurements
Query!
Assessment method [14]
0
0
Vital signs will include body temperature, respiratory rate, blood pressure, and heart rate.
Query!
Timepoint [14]
0
0
Up to approximately 52 months
Query!
Secondary outcome [15]
0
0
Percentage of Participants With Abnormalities in Eastern Cooperative Oncology Group Performance Status (ECOG PS)
Query!
Assessment method [15]
0
0
Query!
Timepoint [15]
0
0
Up to approximately 52 months
Query!
Secondary outcome [16]
0
0
Percentage of Participants With Abnormalities in 12-lead Electrocardiograms (ECGs)
Query!
Assessment method [16]
0
0
Query!
Timepoint [16]
0
0
Up to approximately 52 months
Query!
Secondary outcome [17]
0
0
Percentage of Participants With Abnormalities in Echocardiogram (ECHO) or Multi-Gated Acquisition (MUGA) for Left Ventricular Ejection Fraction (LVEF)
Query!
Assessment method [17]
0
0
LVEF is determined by ECHO or MUGA scan in participants.
Query!
Timepoint [17]
0
0
Up to approximately 52 months
Query!
Secondary outcome [18]
0
0
Percentage of Participants With Abnormalities in Clinical Laboratory Tests
Query!
Assessment method [18]
0
0
Clinical laboratory assessments will include hematology, serum chemistry, coagulation.
Query!
Timepoint [18]
0
0
Up to approximately 52 months
Query!
Secondary outcome [19]
0
0
Percentage of Participants With Adverse Events (AEs)
Query!
Assessment method [19]
0
0
An AE is defined as any untoward medical occurrence in a clinical investigation participant administered an investigational medicinal product; it does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (example, a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug, whether or not it is considered related to the drug.
Query!
Timepoint [19]
0
0
Up to approximately 52 months
Query!
Secondary outcome [20]
0
0
Percentage of Participants With AEs of Special Interest (AESIs)
Query!
Assessment method [20]
0
0
AESIs are AEs that are not solicited local or systemic AEs, they are predefined AEs that required close monitoring and prompt reporting to the sponsor. AESIs include protocol-specified QT prolongation, isocitrate dehydrogenase (IDH) differentiation syndrome and leukocytosis.
Query!
Timepoint [20]
0
0
Up to approximately 52 months
Query!
Secondary outcome [21]
0
0
Percentage of Participants With Serious Adverse Events (SAEs)
Query!
Assessment method [21]
0
0
An SAE is defined as an untoward medical occurrence, significant hazard, contraindication, side effect or precaution that at any dose: results in death, is life-threatening, required in-patient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or is medically significant.
Query!
Timepoint [21]
0
0
Up to approximately 52 months
Query!
Secondary outcome [22]
0
0
Percentage of Participants With Adverse Events Leading to Discontinuation or Death
Query!
Assessment method [22]
0
0
An AE is defined as any untoward medical occurrence in a clinical investigation participant administered an investigational medicinal product; it does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (example, a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug, whether or not it is considered related to the drug.
Query!
Timepoint [22]
0
0
Up to approximately 52 months
Query!
Secondary outcome [23]
0
0
Percentage of Participants Using Concomitant Medications
Query!
Assessment method [23]
0
0
Participants receiving concomitant medications will be adequately monitored by ECG controls, drug concentration (where applicable), and serum electrolytes (i.e., potassium and magnesium).
Query!
Timepoint [23]
0
0
Up to approximately 52 months
Query!
Secondary outcome [24]
0
0
Units of Platelets and Red Blood Cells (RBC) Infused
Query!
Assessment method [24]
0
0
All measures that are indicative of clinical benefit are measured like number of units of platelet and RBC infused.
Query!
Timepoint [24]
0
0
Up to approximately 52 months
Query!
Secondary outcome [25]
0
0
Rate of Infection
Query!
Assessment method [25]
0
0
Query!
Timepoint [25]
0
0
Up to approximately 52 months
Query!
Secondary outcome [26]
0
0
Number of Days Spent Hospitalized
Query!
Assessment method [26]
0
0
Query!
Timepoint [26]
0
0
Up to approximately 52 months
Query!
Secondary outcome [27]
0
0
Change From Baseline in the European Organisation for Research and Treatment of Cancer (EORTC) QLC-C30 Questionnaire
Query!
Assessment method [27]
0
0
The EORTC QLQ-C30 questionnaire measures quality of life and consists of 30 questions that are incorporated into 5 functional domains (physical, role, cognitive, emotional, and social); a global health status/global quality of life; 3 symptom scales (fatigue, pain, and nausea and vomiting); and 6 single items that assess additional symptoms (dyspnea, appetite loss, sleep disturbance, constipation, and diarrhea) and the perceived financial burden of treatment experienced by participants with cancer.
Query!
Timepoint [27]
0
0
Up to approximately 52 months
Query!
Secondary outcome [28]
0
0
Change From Baseline in the EORTC EQ-5D-5L Questionnaire
Query!
Assessment method [28]
0
0
The EORTC EQ-5D-5L questionnaire measures quality of life and spans 5 dimensions, including mobility, self-care, usual activities, pain/discomfort, and anxiety/depression, which are used to build a composite of the participant's health status.
Query!
Timepoint [28]
0
0
Up to approximately 52 months
Query!
Secondary outcome [29]
0
0
Percentage of Participants With CR With IDH1 Mutation Clearance (MC)
Query!
Assessment method [29]
0
0
CR with IDH1 MC is defined as a response of CR where there is no evidence of the IDH1 mutation by molecular techniques to below the level of detection (0.02%-0.04%) for =1 on-treatment time point. A CMH test will be used to compare the rate of CR between 2 treatment arms.
Query!
Timepoint [29]
0
0
Up to approximately 52 months
Query!
Secondary outcome [30]
0
0
Percentage of Participants With Drug Exposure, Dose Modifications and Dose Intensities
Query!
Assessment method [30]
0
0
The number of doses administered, total dose, duration of treatment, dose intensity, and the proportion of participants with dose modifications, will be summarized by treatment arm.
Query!
Timepoint [30]
0
0
Up to approximately 52 months
Query!
Secondary outcome [31]
0
0
Circulating Plasma Concentration of AG-120
Query!
Assessment method [31]
0
0
Serial blood samples will be drawn before and after dosing of study treatment in order to determine circulating plasma concentrations.
Query!
Timepoint [31]
0
0
Up to approximately 52 months
Query!
Secondary outcome [32]
0
0
Circulating Plasma Concentration of 2-HG
Query!
Assessment method [32]
0
0
Serial blood samples will be drawn before and after dosing of study treatment in order to determine circulating plasma concentrations.
Query!
Timepoint [32]
0
0
Up to approximately 52 months
Query!
Eligibility
Key inclusion criteria
1. Be = 18 years of age and meet at least 1 of the following criteria defining
ineligibility for intensive induction chemotherapy (IC): = 75 years old, Eastern
Cooperative Oncology Group Performance Status (ECOG PS) score of 2, severe cardiac
disorder (e.g., congestive heart failure requiring treatment, left ventricular
ejection fraction (LVEF), =50%, or chronic stable angina), severe pulmonary disorder
(e.g., diffusing capacity of the lungs for carbon monoxide =65% or forced expiratory
volume in 1 second =65%), creatinine clearance <45 mL/minute, bilirubin >1.5 times the
upper limit of normal (ULN) and/or have any other comorbidity that the Investigator
judges to be incompatible with intensive IC and must be reviewed and approved by the
Medical Monitor before study enrollment.
2. Have previously untreated AML, defined according to World Health Organization (WHO)
criteria, with = 20% leukemic blasts in the bone marrow. Participants with
extramedullary disease alone (i.e., no detectable bone marrow and no detectable
peripheral blood AML) are not eligible for the study.
3. Have an isocitrate dehydrogenase 1 (IDH1) mutation.
4. Have an ECOG PS score of 0 to 2.
5. Have adequate hepatic function.
6. Have adequate renal function.
7. Have agreed to undergo serial blood and bone marrow sampling.
8. Be able to understand and willing to sign an informed consent form (ICF).
9. Be willing to complete Quality of Life assessments during the study
10. If female with reproductive potential, must have a negative serum pregnancy test prior
to the start of study therapy. Females of reproductive potential, as well as fertile
men and their female partners of reproductive potential, must agree to use 2 effective
forms of contraception.
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
1. Are candidates for and willing to receive intensive induction chemotherapy (IC) for
their AML.
2. Have received any prior treatment for AML with the exception of hydroxyurea.
3. Have received a hypomethylating agent for myelodysplastic syndrome (MDS).
4. Participants who had previously received an experimental agent for MDS may not be
randomized until a washout period has elapsed since the last dose of that agent.
5. Have received prior treatment with an IDH1 inhibitor.
6. Have a known hypersensitivity to any of the components of AG-120, matched placebo, or
azacitidine.
7. Are female and pregnant or breastfeeding.
8. Have an active, uncontrolled, systemic fungal, bacterial, or viral infection without
improvement despite appropriate antibiotics, antiviral therapy, and/or other
treatment.
9. Have a prior history of cancer other than MDS or myeloproliferative disorder, unless
the participant has been free of the disease for = 1 year prior to the start of study
treatment.
10. Have had significant active cardiac disease within 6 months prior to the start of the
study treatment.
11. Have any condition that increases the risk of abnormal ECG or cardiac arrhythmia.
12. Have a condition that limits the ingestion or absorption of drugs administered by
mouth.
13. Have uncontrolled hypertension (systolic blood pressure [BP] > 180 mmHg or diastolic
BP > 100 mmHg).
14. Have clinical symptoms suggestive of active central nervous system (CNS) leukemia or
known CNS leukemia.
15. Have immediate, life-threatening, severe complications of leukemia, such as
uncontrolled bleeding, pneumonia with hypoxia or sepsis, and/or disseminated
intravascular coagulation.
16. Have any other medical or psychological condition deemed by the Investigator to be
likely to interfere with the participant's ability to give informed consent or
participate in the study.
17. Are taking medications that are known to prolong the QT interval unless they can be
transferred to other medications within =5 half-lives prior to dosing, or unless the
medications can be properly monitored during the study. (If equivalent medication is
not available, heart rate corrected QT interval [QTc] will be closely monitored.)
18. Have a known medical history of progressive multifocal leukoencephalopathy.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Active, not recruiting
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
26/06/2017
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
30/06/2026
Query!
Actual
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
146
Query!
Recruitment in Australia
Recruitment state(s)
NSW,SA
Query!
Recruitment hospital [1]
0
0
Royal Prince Alfred Hospital - Camperdown
Query!
Recruitment hospital [2]
0
0
Royal Adelaide Hospital - Adelaide
Query!
Recruitment hospital [3]
0
0
Flinders Medical Centre - Bedford park
Query!
Recruitment postcode(s) [1]
0
0
2050 - Camperdown
Query!
Recruitment postcode(s) [2]
0
0
5000 - Adelaide
Query!
Recruitment postcode(s) [3]
0
0
5042 - Bedford park
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Kentucky
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Massachusetts
Query!
Country [3]
0
0
Austria
Query!
State/province [3]
0
0
Salzburg
Query!
Country [4]
0
0
Austria
Query!
State/province [4]
0
0
Wien
Query!
Country [5]
0
0
Brazil
Query!
State/province [5]
0
0
Sao Paulo
Query!
Country [6]
0
0
Brazil
Query!
State/province [6]
0
0
Rio De Janeiro
Query!
Country [7]
0
0
Canada
Query!
State/province [7]
0
0
Manitoba
Query!
Country [8]
0
0
Canada
Query!
State/province [8]
0
0
Ontario
Query!
Country [9]
0
0
China
Query!
State/province [9]
0
0
Henan
Query!
Country [10]
0
0
China
Query!
State/province [10]
0
0
Sichuan
Query!
Country [11]
0
0
China
Query!
State/province [11]
0
0
Beijing
Query!
Country [12]
0
0
China
Query!
State/province [12]
0
0
Guangzhou
Query!
Country [13]
0
0
China
Query!
State/province [13]
0
0
Hangzhou
Query!
Country [14]
0
0
China
Query!
State/province [14]
0
0
Tianjin
Query!
Country [15]
0
0
Czechia
Query!
State/province [15]
0
0
Ostrava
Query!
Country [16]
0
0
France
Query!
State/province [16]
0
0
Gironde
Query!
Country [17]
0
0
France
Query!
State/province [17]
0
0
Indre-et-Loire
Query!
Country [18]
0
0
France
Query!
State/province [18]
0
0
Loire-Atlantique
Query!
Country [19]
0
0
France
Query!
State/province [19]
0
0
Rhone
Query!
Country [20]
0
0
France
Query!
State/province [20]
0
0
Sarthe
Query!
Country [21]
0
0
France
Query!
State/province [21]
0
0
Brest
Query!
Country [22]
0
0
France
Query!
State/province [22]
0
0
Caen
Query!
Country [23]
0
0
France
Query!
State/province [23]
0
0
Grenoble
Query!
Country [24]
0
0
France
Query!
State/province [24]
0
0
Le Chesnay
Query!
Country [25]
0
0
France
Query!
State/province [25]
0
0
Paris
Query!
Country [26]
0
0
France
Query!
State/province [26]
0
0
Poitiers
Query!
Country [27]
0
0
France
Query!
State/province [27]
0
0
Strasbourg
Query!
Country [28]
0
0
France
Query!
State/province [28]
0
0
Toulouse
Query!
Country [29]
0
0
France
Query!
State/province [29]
0
0
Villejuif
Query!
Country [30]
0
0
Germany
Query!
State/province [30]
0
0
Nordrhein-Westfalen
Query!
Country [31]
0
0
Germany
Query!
State/province [31]
0
0
Sachsen
Query!
Country [32]
0
0
Germany
Query!
State/province [32]
0
0
Berlin
Query!
Country [33]
0
0
Germany
Query!
State/province [33]
0
0
Hannover
Query!
Country [34]
0
0
Germany
Query!
State/province [34]
0
0
Leipzig
Query!
Country [35]
0
0
Germany
Query!
State/province [35]
0
0
Munchen
Query!
Country [36]
0
0
Germany
Query!
State/province [36]
0
0
Ulm
Query!
Country [37]
0
0
Israel
Query!
State/province [37]
0
0
Petah Tikva
Query!
Country [38]
0
0
Israel
Query!
State/province [38]
0
0
Rehovot
Query!
Country [39]
0
0
Italy
Query!
State/province [39]
0
0
Lombardia
Query!
Country [40]
0
0
Italy
Query!
State/province [40]
0
0
Meldola
Query!
Country [41]
0
0
Italy
Query!
State/province [41]
0
0
Milano
Query!
Country [42]
0
0
Italy
Query!
State/province [42]
0
0
Pavia
Query!
Country [43]
0
0
Italy
Query!
State/province [43]
0
0
Rimini
Query!
Country [44]
0
0
Italy
Query!
State/province [44]
0
0
Torino
Query!
Country [45]
0
0
Japan
Query!
State/province [45]
0
0
Ehime
Query!
Country [46]
0
0
Japan
Query!
State/province [46]
0
0
Fukui
Query!
Country [47]
0
0
Japan
Query!
State/province [47]
0
0
Himeji
Query!
Country [48]
0
0
Japan
Query!
State/province [48]
0
0
Kobe
Query!
Country [49]
0
0
Korea, Republic of
Query!
State/province [49]
0
0
Gyeonggido
Query!
Country [50]
0
0
Korea, Republic of
Query!
State/province [50]
0
0
Busan
Query!
Country [51]
0
0
Korea, Republic of
Query!
State/province [51]
0
0
Seoul
Query!
Country [52]
0
0
Mexico
Query!
State/province [52]
0
0
Culiacan
Query!
Country [53]
0
0
Mexico
Query!
State/province [53]
0
0
Mexico
Query!
Country [54]
0
0
Netherlands
Query!
State/province [54]
0
0
Noord-Holland
Query!
Country [55]
0
0
Netherlands
Query!
State/province [55]
0
0
Nijmegen
Query!
Country [56]
0
0
Poland
Query!
State/province [56]
0
0
Dolnoslaskie
Query!
Country [57]
0
0
Poland
Query!
State/province [57]
0
0
Mazowieckie
Query!
Country [58]
0
0
Poland
Query!
State/province [58]
0
0
Gdansk
Query!
Country [59]
0
0
Russian Federation
Query!
State/province [59]
0
0
Kaluga
Query!
Country [60]
0
0
Russian Federation
Query!
State/province [60]
0
0
Moscow
Query!
Country [61]
0
0
Spain
Query!
State/province [61]
0
0
A Coruna
Query!
Country [62]
0
0
Spain
Query!
State/province [62]
0
0
Baleares
Query!
Country [63]
0
0
Spain
Query!
State/province [63]
0
0
Barcelona
Query!
Country [64]
0
0
Spain
Query!
State/province [64]
0
0
Las Palmas
Query!
Country [65]
0
0
Spain
Query!
State/province [65]
0
0
Madrid
Query!
Country [66]
0
0
Spain
Query!
State/province [66]
0
0
Sevilla
Query!
Country [67]
0
0
Spain
Query!
State/province [67]
0
0
Valencia
Query!
Country [68]
0
0
Spain
Query!
State/province [68]
0
0
Zaragoza
Query!
Country [69]
0
0
Taiwan
Query!
State/province [69]
0
0
Changhua City
Query!
Country [70]
0
0
Taiwan
Query!
State/province [70]
0
0
Kaohsiung
Query!
Country [71]
0
0
Taiwan
Query!
State/province [71]
0
0
Taichung City
Query!
Country [72]
0
0
Taiwan
Query!
State/province [72]
0
0
Tainan City
Query!
Country [73]
0
0
Taiwan
Query!
State/province [73]
0
0
Taipei
Query!
Country [74]
0
0
United Kingdom
Query!
State/province [74]
0
0
West Midlands
Query!
Funding & Sponsors
Primary sponsor type
Other
Query!
Name
Institut de Recherches Internationales Servier
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
Study AG120-C-009 is a global, Phase 3, multicenter, double-blind, randomized,
placebo-controlled clinical trial to evaluate the efficacy and safety of AG-120 (ivosidenib)
+ azacitidine vs placebo + azacitidine in adult participants with previously untreated IDH1m
AML who are considered appropriate candidates for non-intensive therapy. The primary endpoint
is event-free survival (EFS). The key secondary efficacy endpoints are overall survival (OS),
rate of complete remission (CR), rate of CR and complete remission with partial hematologic
recovery (CRh), and overall response rate (ORR). Participants eligible for study treatment
based on Screening assessments will be randomized 1:1 to receive oral AG-120 or matched
placebo, both administered in combination with subcutaneous (SC) or intravenous (IV)
azacitidine. An estimated 200 participants will take part in the study.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT03173248
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT03173248
Download to PDF